Scholar Rock to Sell FDA Priority Review Voucher to BioNTech for $205 Million
Scholar Rock (SRRK) agreed to sell its FDA Priority Review Voucher to BioNTech for $205M in cash. The payment is due at closing, pending regulatory approval. The voucher was awarded after FDA approval of ISEMBYLD. The transaction aims to monetize the voucher.
How this was made
The 30-second read
Why it matters
The $205 M voucher sale provides a significant non‑dilutive capital boost, potentially improving earnings outlook and share valuation.
Market read
First‑report, material M&A deal in biotech sector; likely to move SRRK stock.
What to watch
Closing is subject to HSR waiting period; any delay could affect timing of cash receipt.
Background
Scholar Rock (SRRK) holds a Rare Pediatric Disease Priority Review Voucher earned from FDA approval of ISEMBYLD.
Ticker impact
Scholar Rock disclosed a $205 million sale of its FDA priority review voucher to BioNTech.
upward pressure as market prices in the cash inflow
The transaction is a material, first‑report deal that directly adds $205 M to SRRK's assets.
Market effects
Highlights value of FDA priority review vouchers in biotech M&A.
US biotech investors may view voucher sales as a new liquidity source.
Shows BioNTech's willingness to acquire rare‑disease vouchers, signaling strategic interest.
Counterpoint
Voucher buyers may overpay if regulatory timelines shift, limiting upside for SRRK.
Key entities
- companyScholar Rock Holding Corp
Seller of the FDA priority review voucher.
- companyBioNTech SE
Buyer of the voucher.
